Cargando…
BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis
BACKGROUND: BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. METHODS: We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that estimated PCa RRs for male...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979955/ https://www.ncbi.nlm.nih.gov/pubmed/34963702 http://dx.doi.org/10.1038/s41416-021-01675-5 |
_version_ | 1784681290834903040 |
---|---|
author | Nyberg, Tommy Tischkowitz, Marc Antoniou, Antonis C. |
author_facet | Nyberg, Tommy Tischkowitz, Marc Antoniou, Antonis C. |
author_sort | Nyberg, Tommy |
collection | PubMed |
description | BACKGROUND: BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. METHODS: We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that estimated PCa RRs for male BRCA1/2 carriers, with no time or language restrictions. The literature search identified 27 studies (BRCA1: n = 20, BRCA2: n = 21). RESULTS: The heterogeneity between the published estimates was high (BRCA1: I(2) = 30%, BRCA2: I(2) = 83%); this could partly be explained by selection for age, family history or aggressive disease, and study-level differences in ethnicity composition, use of historical controls, and location of PVs within BRCA2. The pooled RRs were 2.08 (95% CI 1.38–3.12) for Ashkenazi Jewish BRCA2 carriers, 4.35 (95% CI 3.50–5.41) for non-Ashkenazi European ancestry BRCA2 carriers, and 1.18 (95% CI 0.95–1.47) for BRCA1 carriers. At ages <65 years, the RRs were 7.14 (95% CI 5.33–9.56) for non-Ashkenazi European ancestry BRCA2 and 1.78 (95% CI 1.09–2.91) for BRCA1 carriers. CONCLUSIONS: These PCa risk estimates will assist in guiding clinical management. The study-level subgroup analyses indicate that risks may be modified by age and ethnicity, and for BRCA2 carriers by PV location within the gene, which may guide future risk-estimation studies. |
format | Online Article Text |
id | pubmed-8979955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-89799552022-04-20 BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis Nyberg, Tommy Tischkowitz, Marc Antoniou, Antonis C. Br J Cancer Article BACKGROUND: BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. METHODS: We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that estimated PCa RRs for male BRCA1/2 carriers, with no time or language restrictions. The literature search identified 27 studies (BRCA1: n = 20, BRCA2: n = 21). RESULTS: The heterogeneity between the published estimates was high (BRCA1: I(2) = 30%, BRCA2: I(2) = 83%); this could partly be explained by selection for age, family history or aggressive disease, and study-level differences in ethnicity composition, use of historical controls, and location of PVs within BRCA2. The pooled RRs were 2.08 (95% CI 1.38–3.12) for Ashkenazi Jewish BRCA2 carriers, 4.35 (95% CI 3.50–5.41) for non-Ashkenazi European ancestry BRCA2 carriers, and 1.18 (95% CI 0.95–1.47) for BRCA1 carriers. At ages <65 years, the RRs were 7.14 (95% CI 5.33–9.56) for non-Ashkenazi European ancestry BRCA2 and 1.78 (95% CI 1.09–2.91) for BRCA1 carriers. CONCLUSIONS: These PCa risk estimates will assist in guiding clinical management. The study-level subgroup analyses indicate that risks may be modified by age and ethnicity, and for BRCA2 carriers by PV location within the gene, which may guide future risk-estimation studies. Nature Publishing Group UK 2021-12-28 2022-04-01 /pmc/articles/PMC8979955/ /pubmed/34963702 http://dx.doi.org/10.1038/s41416-021-01675-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Nyberg, Tommy Tischkowitz, Marc Antoniou, Antonis C. BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis |
title | BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis |
title_full | BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis |
title_fullStr | BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis |
title_full_unstemmed | BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis |
title_short | BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis |
title_sort | brca1 and brca2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979955/ https://www.ncbi.nlm.nih.gov/pubmed/34963702 http://dx.doi.org/10.1038/s41416-021-01675-5 |
work_keys_str_mv | AT nybergtommy brca1andbrca2pathogenicvariantsandprostatecancerrisksystematicreviewandmetaanalysis AT tischkowitzmarc brca1andbrca2pathogenicvariantsandprostatecancerrisksystematicreviewandmetaanalysis AT antoniouantonisc brca1andbrca2pathogenicvariantsandprostatecancerrisksystematicreviewandmetaanalysis |